Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 1;9(9):1871-1888.
eCollection 2019.

Promising new treatments for pancreatic cancer in the era of targeted and immune therapies

Ahmed Elaileh  1 , Ashish Saharia  1 , Lucy Potter  1 , Flavio Baio  1 , Afnan Ghafel  2 , Maen Abdelrahim  1 , Kirk Heyne  1
Affiliations
Review

Promising new treatments for pancreatic cancer in the era of targeted and immune therapies

Ahmed Elaileh et al. Am J Cancer Res. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality among men and women in the United States. Its incidence has been on the rise, with a projected two-fold increase by 2030. PDAC carries a poor prognosis due to a lack of effective screening tools, limited understanding of pathophysiology, and ineffective treatment modalities. Recently, there has been a revolution in the world of oncology with the advent of novel treatments to combat this disease. However, the 5-year survival of PDAC remains unchanged at a dismal 8%. The aim of this review is to bring together several studies and identify various recent modalities that have been promising in treating PDAC.

Keywords: BRCA; Pancreatic cancer; cancer vaccine; check point inhibitor; hypoxia induced resistance; immunotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Cell Signal Transduction.
Figure 2
Figure 2
Alk-EML4/HSP90 interplay.
See this image and copyright information in PMC

References

    1. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355–385. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Zhou J, Enewold L, Stojadinovic A, Clifton GT, Potter JF, Peoples GE, Zhu K. Incidence rates of exocrine and endocrine pancreatic cancers in the united states. Cancer Causes Control. 2010;21:853–861. - PubMed
    1. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766–1773. - PubMed
    1. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–987. - PubMed

LinkOut - more resources